You are here: Industry Insights > hemophilia B

News List

Belief Biomed's Gene Therapy for Hemophilia B Receives NMPA IND Approval: First Intravenous Infusion Gene Therapy for Rare Disease in China prnasia
August 11, 2021
On August 10th, 2021，Belief Biomed announced that China's National Medical Products Administration (NMPA) has cleared the IND (Investigational New Drug) application for Belief Biomed's BBM-H901.
Freeline modifies clinical development plan for Hemophilia B programme pharmaceutical-technology
February 10, 2021
Clinical-stage biotechnology company Freeline Therapeutics has announced a modification to the clinical development plan for its FLT180a programme for Hemophilia B.
Novo Nordisk launches Rebinyn, a new, long-acting treatment for patients with hemophilia B in Canada biospace
April 12, 2018
Novo Nordisk announced the launch and availability of Rebinyn® (Coagulation Factor IX (Recombinant), pegylated)
Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B worldpharmanews
November 09, 2017
Spark Therapeutics (NASDAQ: ONCE) and Pfizer (NYSE: PFE) have amended their license agreement for hemophilia B's investigational gene therapy, SPK-9001
UniQure, chasing Spark-level FIX activity, tweaks hemophilia B gene therapy ahead of 2018 pivotal tr fiercebiotech
October 20, 2017
UniQure has modified its hemophilia B gene therapy to dial up factor IX (FIX) activity to the levels achieved by Spark Therapeutics’ rival product.